Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B

Human cytomegalovirus (HCMV) is associated with significant morbidity and mortality following immunosuppression and in pregnancy. HCMV infection may be accompanied by acute disease but persists asymptomatically. Cytotoxic T lymphocytes (CTL) appear to be an important immune effector mechanism in maintaining the normal host‐virus equilibrium. Glycoprotein B may be an important target for future subunit vaccines as it has been found to elicit both neutralising antibody and CTL responses.

[1]  F. Bach,et al.  Molecular analysis of the immune response to human cytomegalovirus glycoprotein B (gB). II. Low gB-specific T and B cell responses are associated with expression of certain HLA-DR alleles. , 1994, The Journal of general virology.

[2]  S. Riddell,et al.  Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus , 1993, Journal of virology.

[3]  W. Britt,et al.  Virus-specific antibody responses in mothers and their newborn infants with asymptomatic congenital cytomegalovirus infections. , 1993, The Journal of infectious diseases.

[4]  J. Coligan,et al.  Presentation of three different viral peptides, HTLV-1 Tax, HCMV gB, and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule. , 1992, Journal of immunology.

[5]  S. Riddell,et al.  Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients. , 1991, Reviews of infectious diseases.

[6]  N. Alp,et al.  Fine specificity of cellular immune responses in humans to human cytomegalovirus immediate-early 1 protein , 1991, Journal of virology.

[7]  M. Stinski,et al.  The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B- and T-cell immune responses in humans , 1991, Journal of virology.

[8]  H. Friedman,et al.  Vaccines for the prevention of human cytomegalovirus infection. , 1990, Reviews of infectious diseases.

[9]  W. Britt,et al.  Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response , 1990, Journal of virology.

[10]  J. Sissons,et al.  Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses , 1988, The Journal of experimental medicine.

[11]  M. Stinski,et al.  Characterization of a human cytomegalovirus glycoprotein complex (gcI). , 1988, The Journal of general virology.

[12]  M. Stinski,et al.  Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus , 1988, Journal of virology.

[13]  J. Sissons,et al.  Human cytomegalovirus‐specific cytotoxic T cells: their precursor frequency and stage specificity , 1988, European journal of immunology.

[14]  U. Koszinowski,et al.  CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity , 1987, Journal of virology.

[15]  J. Bull,et al.  Prospects for the clinical management of human cytomegalovirus infections. , 1986, Vaccine.

[16]  B. Barrell,et al.  Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. , 1986, The EMBO journal.

[17]  J. Booth,et al.  An early marker of fetal infection after primary cytomegalovirus infection in pregnancy. , 1986 .

[18]  W. Britt.  Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. , 1984, Virology.

[19]  L. Borysiewicz,et al.  Human cytomegalovirus‐specific cytotoxic T lymphocytes: requirements for in vitro generation and specificity , 1983, European journal of immunology.

[20]  B. Roizman.  The Family Herpesviridae: General Description, Taxonomy, and Classification , 1982 .

[21]  C. Prober,et al.  Prevention of transfusion-acquired cytomegalovirus infections in newborn infants , 1981 .

[22]  P. Terasaki,et al.  Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. , 1978, American journal of clinical pathology.

[23]  Richard Smith,et al.  Congenital cytomegalovirus infection. , 1977, The New England journal of medicine.

[24]  U. Krech.  Complement-fixing antibodies against cytomegalovirus in different parts of the world. , 1973, Bulletin of the World Health Organization.

[25]  D. Medearis,et al.  Recovery of cytomegalovirus from the cervix in pregnancy. , 1972, Pediatrics.